ERBB2 and breast cancer: conducted a study including 117 breast cancer patients (with hormone-receptor-positive, HER2-negative, triple-negative, and HER2-positive disease) and showed that combined peritumoral and tumoral radiomic features obtained at baseline could be utilized to predict pCR to neoadjuvant chemotherapy (22).